Amplify Weight Loss Drug & Treatment ETF (THNR) is a Amplify ETF with a 0.59% expense ratio, 21 holdings and $5.7MM in net assets. Largest sector: Healthcare (100%).
Fee
0.59%
expense ratio
Net assets
$5.7MM
Launched
May 21, 2024
Holdings
21
as of Oct 26, 2026
Top 10 weight
65.7%
largest ten holdings
Largest sector
Healthcare
100.0%
Yield
30-day SEC 0.98% · TTM 1.64%
as of Sep 30, 2026
Benchmark
—
THNR's holdings are as of Oct 26, 2026.
Healthcare
100.0%
1
LLY
ELI LILLY
11.28%
2
NVO
Novo Nordisk A/S
8.83%
3
AMGN
AMGEN
6.10%
4
ROP
Roche Holding AG
5.91%
5
ABBV
ABBVIE
5.78%
6
PFE
PFIZER
5.76%
7
AZN
ASTRAZENECA
5.70%
8
GILD
GILEAD SCIENCES
5.56%
9
REGN
REGENERON PHARMACEUTICALS
5.39%
10
4519
Chugai Pharmaceutical Ltd
5.35%
11
MRK
MERCK
5.18%
12
1093
CSPC Pharmaceutical Group Ltd
4.91%
13
1801
Innovent Biologics
4.58%
14
VKTX
Viking Therapeutics
3.92%
15
ARWR
Arrowhead Pharmaceuticals
3.62%
16
ZEAL
Zealand Pharma A/S
3.31%
17
128940
Hanmi Pharm Ltd
2.65%
18
1276
Jiangsu Hengrui Pharmaceuticals Ltd
2.30%
19
GPCR
STRUCTURE THERAPEUTICS
2.28%
20
KLRA
Kailera Therapeutics
1.13%
21
AGPXX
Invesco Government & Agency Portfolio
0.26%
1–21 of 21
Funds listed by how much of their largest holdings they share with THNR — not a ranking.
Data from Amplify; prices and returns from market data. Page updated October 29, 2026. Holdings and figures change over time. For information only — not investment advice.